Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer...

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• Tumors deficient in BRCA1 and BRCA2 (BRCA) genes exhibit increased sensitivity to DNA-damaging agents like poly (ADP-ribose) polymerase 1 (PARP1) inhibitors.
• Acquired resistance to PARP1 inhibitors in BRCA-deficient cancers presents a significant clinical challenge, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate mechanisms of resistance to PARP1 inhibitors in BRCA1-deficient cells.
• To explore novel therapeutic strategies targeting DNA repair pathways in BRCA-deficient cancers.

Main Methods:

• Utilized CRISPR technology for genetic screening in BRCA1-deficient cancer cells.
• Assessed DNA end resection, homologous recombination, and sensitivity to DNA nicks and PARP1 inhibitors.
• Investigated the role of the 53BP1-Shieldin complex in DNA repair and drug resistance.

Main Results:

• Loss of the 53BP1-Shieldin complex in BRCA1-deficient cells enhances homologous recombination by increasing DNA end resection.
• This enhanced resection leads to heightened sensitivity to DNA nicks, causing cell death via hyper-resection into single-stranded DNA.
• The 53BP1-Shieldin complex plays a critical role in restricting nick expansion, and its loss sensitizes cells to nicks.

Conclusions:

• Targeting DNA repair pathways, specifically by modulating homologous recombination and DNA end resection, can overcome resistance to PARP1 inhibitors.
• The 53BP1-Shieldin complex is a key regulator of DNA repair and drug resistance, and its inhibition is a potential therapeutic strategy.
• DNA nickases show promise as a tool for personalized medicine in treating BRCA-deficient tumors, leveraging the heightened sensitivity to DNA nicks.